Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.

NCT06927466 is registered in ClinicalTrials.gov with Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd. as lead sponsor.

NCT NCT06927466
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06927466 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
Lead sponsor
Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
September 19, 2024
Completion date
June 30, 2028
Enrollment
33 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory b-cell acute lymphoblastic leukemia